

Dimethyl 3-(4-bromobenzoyl)-7-(*N,N*-dimethylamino)indolizine-1,2-dicarboxylate

R. Hema,^a V. Parthasarathi,^{a*}
K. Sarkunam,^b M. Nallu^b and
Anthony Linden^c

^aDepartment of Physics, Bharathidasan University, Tiruchirappalli-620 024, India,

^bDepartment of Chemistry, Bharathidasan University, Tiruchirappalli-620 024, India, and

^cInstitute of Organic Chemistry, University of Zürich, Winterthurerstrasse 190, CH-8057 Zürich, Switzerland

Correspondence e-mail: vpsarati@yahoo.com

Key indicators

Single-crystal X-ray study

$T = 160\text{ K}$

Mean $\sigma(\text{C}-\text{C}) = 0.003\text{ \AA}$

R factor = 0.038

wR factor = 0.101


Data-to-parameter ratio = 21.4

For details of how these key indicators were automatically derived from the article, see <http://journals.iucr.org/e>.

In the title compound, $\text{C}_{21}\text{H}_{19}\text{BrN}_2\text{O}_5$, the planes of the two methoxycarbonyl moieties are oriented at angles of $7.70(6)$ and $69.09(6)^\circ$ with respect to that of the indolizine ring. In the solid state, the molecules are held together by weak intermolecular $\text{C}-\text{H}\cdots\text{O}$ and $\text{C}-\text{H}\cdots\text{Br}$ interactions which form chain and centrosymmetric ring motifs.

Comment

The synthesis of biologically active indolizine derivatives continues to attract the attention of organic chemists, because they are important as potential central nervous system depressants, calcium entry blockers, cardiovascular agents, spectral sensitizers and novel dyes (Gubin *et al.*, 1992; Bora *et al.*, 2003). Indolizines have also been tested as anti-mycobacterial agents against mycobacterial tuberculosis (Gundersen *et al.*, 2003).



The structural investigation of the title compound, (I) (Fig. 1), has been undertaken as a part of our study on the conformational changes caused by different substituents at various positions on the indolizine ring system. The bond lengths and angles in (I) are comparable with those in related structures (Pritchard, 1988; Hema *et al.*, 2003). The non-H atoms of (I) common to two related indolizine derivatives, *viz.* 3-(4-chlorobenzoyl)-7-(*N,N*-dimethylamino)-1-phenylindolizine and 3-(2,4-dichlorobenzoyl)-7-(*N,N*-dimethylamino)-1-




Figure 1

View of (I) with the atom-labelling scheme. Displacement ellipsoids are drawn at the 50% probability level. H atoms are represented by circles of arbitrary radii.

phenylindolizine (Hema *et al.*, 2003), were superimposed on the corresponding atoms of these latter compounds and the r.m.s. deviations were found to be 0.958 and 0.965 Å, respectively. The planes of the two methoxycarbonyl moieties deviate from the plane of the indolizine ring to different extents, the angles between the latter plane and those of the C1/C10/O10/O11/C11 and C2/C12/O12/O13/C13 moieties being 7.70 (6) and 69.09 (6)°, respectively. The dihedral angle between the planes of the bromophenyl ring and the indolizine ring system is 68.34 (5)°, while the plane of the carbonyl moiety C2/C14/O14/C15 lies roughly between these two orientations and makes angles of 59.39 (6) and 20.69 (5)°, respectively, with the planes of the bromophenyl ring and the indolizine ring system.

The crystal packing is stabilized by a number of weak intermolecular C—H···O and C—H···Br interactions (Table 1). The C—H···Br interaction links pairs of molecules across centres of inversion to give the ring motif $R_2^2(24)$ (Bernstein *et al.*, 1995).

Experimental

A mixture of 4-dimethylaminopyridinium 1-(4-bromo)phenacylide (1.4 mmol), dimethylacetylene dicarboxylate (1.6 mmol) and potassium carbonate (1.6 mmol) in dimethylformamide (30 ml) was kept at room temperature overnight. The insoluble materials were removed by filtration. The filtrate was extracted with an ethyl acetate–dilute HCl mixture. The organic layer was evaporated and chromatographed to give (I), which was recrystallized from ethyl acetate (yield, 0.29 g, 55%; m.p. 474–476 K).

Crystal data

$C_{21}H_{19}BrN_2O_5$	$Z = 2$
$M_r = 459.29$	$D_x = 1.570 \text{ Mg m}^{-3}$
Triclinic, $P\bar{1}$	Mo $K\alpha$ radiation
$a = 7.5238 (2) \text{ \AA}$	Cell parameters from 29 442 reflections
$b = 10.2817 (2) \text{ \AA}$	$\theta = 2.0\text{--}30.0^\circ$
$c = 13.8084 (2) \text{ \AA}$	$\mu = 2.15 \text{ mm}^{-1}$
$\alpha = 69.467 (1)^\circ$	$T = 160 (2) \text{ K}$
$\beta = 79.837 (1)^\circ$	Prism, yellow
$\gamma = 77.741 (1)^\circ$	$0.30 \times 0.23 \times 0.20 \text{ mm}$
$V = 971.42 (3) \text{ \AA}^3$	

Data collection

Nonius KappaCCD diffractometer	4679 reflections with $I > 2\sigma(I)$
φ and ω scans with κ offsets	$R_{\text{int}} = 0.068$
Absorption correction: multi-scan (SORTAV; Blessing, 1995)	$\theta_{\text{max}} = 30.0^\circ$
$T_{\text{min}} = 0.542$, $T_{\text{max}} = 0.641$	$h = -10 \rightarrow 10$
25900 measured reflections	$k = -14 \rightarrow 14$
5684 independent reflections	$l = -19 \rightarrow 18$

Refinement

Refinement on F^2	$w = 1/[\sigma^2(F_o^2) + (0.0525P)^2 + 0.3259P]$
$R[F^2 > 2\sigma(F^2)] = 0.038$	where $P = (F_o^2 + 2F_c^2)/3$
$wR(F^2) = 0.101$	$(\Delta/\sigma)_{\text{max}} = 0.001$
$S = 1.03$	$\Delta\rho_{\text{max}} = 0.38 \text{ e \AA}^{-3}$
5684 reflections	$\Delta\rho_{\text{min}} = -0.66 \text{ e \AA}^{-3}$
266 parameters	
H-atom parameters constrained	

Table 1
Hydrogen-bonding geometry (Å, °).

$D\text{---}H\cdots A$	$D\text{---}H$	$H\cdots A$	$D\cdots A$	$D\text{---}H\cdots A$
C13—H133···O12 ⁱ	0.98	2.45	3.419 (3)	170
C17—H17···O10 ⁱⁱ	0.95	2.50	3.368 (2)	152
C19—H19···O10 ⁱⁱⁱ	0.95	2.31	3.249 (2)	172
C23—H233···O14 ^{iv}	0.98	2.44	3.167 (2)	131
C13—H131···Br ^v	0.98	2.84	3.480 (2)	123

Symmetry codes: (i) $1 - x, 1 - y, 1 - z$; (ii) $x, y - 1, z$; (iii) $1 + x, y - 1, z$; (iv) $1 - x, 2 - y, -z$; (v) $1 - x, -y, 1 - z$.

The methyl H atoms were constrained to an ideal geometry (C—H = 0.98 Å), with U_{iso} values of $1.5U_{\text{eq}}(\text{C})$, but were allowed to rotate freely about the C—C bond. All remaining H atoms were placed in idealized positions (C—H = 0.95 Å) and constrained to ride on their parent atoms, with $U_{\text{iso}}(\text{H})$ values of $1.2U_{\text{eq}}(\text{C})$.

Data collection: COLLECT (Nonius, 2000); cell refinement: DENZO-SMN (Otwinowski & Minor, 1997); data reduction: DENZO-SMN and SCALEPACK (Otwinowski & Minor, 1997); program(s) used to solve structure: SIR92 (Altomare *et al.*, 1994); program(s) used to refine structure: SHELXL97 (Sheldrick, 1997); molecular graphics: ORTEP-3 (Version 1.07; Farrugia, 1997); software used to prepare material for publication: SHELXL97 and PLATON (Spek, 2003).

Thanks are due to the Council of Scientific and Industrial Research (CSIR), India, for the award of a Senior Research Fellowship (2001–2004) to KS. RH thanks the UGC, India, for the award of a Minor Research Project.

References

- Altomare, A., Cascarano, G., Giacovazzo, C., Guagliardi, A., Burla, M. C., Polidori, G. & Camalli, M. (1994). *J. Appl. Cryst.* **27**, 435.
 Bernstein, J., Davis, R. E., Shimon, L. & Chang, N.-L. (1995). *Angew. Chem. Int. Ed. Engl.* **34**, 1555–1573.
 Blessing, R. H. (1995). *Acta Cryst.* **A51**, 33–38.
 Bora, U., Saikia, A. & Boruah, R. C. (2003). *Org. Lett.* **5**, 435–438.
 Farrugia, L. J. (1997). *J. Appl. Cryst.* **30**, 565.
 Gubin, J., Lucchetti, J., Mahaux, J., Nisato, D., Rosseels, G., Clinet, M., Polster, P. & Chatelain, P. (1992). *J. Med. Chem.* **35**, 981–988.
 Gundersen, L. L., Negussie, A. H., Rise, F. & Ostby, O. B. (2003). *Arch. Pharm. (Weinheim)*, **336**, 191–195.
 Hema, R., Parthasarathi, V., Sarkunam, K., Nallu, M. & Linden, A. (2003). *Acta Cryst.* **C59**, o703–o705.
 Nonius (2000). COLLECT. Nonius BV, Delft, The Netherlands.
 Otwinowski, Z. & Minor, W. (1997). *Methods in Enzymology*, Vol. 276, *Macromolecular Crystallography*, Part A, edited by C. W. Carter Jr & R. M. Sweet, pp. 307–326. New York: Academic Press.
 Pritchard, R. G. (1988). *Acta Cryst.* **C44**, 1150–1152.
 Sheldrick, G. M. (1997). SHELXL97. University of Göttingen, Germany.
 Spek, A. L. (2003). *J. Appl. Cryst.* **36**, 7–13.